Nachtnebel, A. (2011): Rituximab (Rituxan®/MabThera®)for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011. DSD: Horizon Scanning in Oncology 04 / Update 2011.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Rituximab, an anti-CD20 monoclonal antibody, is licensed for previously treated and previously untreated patients suffering from chronic lymphocytic leukaemia in Europe. Of note, the chemotherapy regimen rituximab should be combined with is not further defined in Europe, whereas rituximab is licensed only in combination with FC in the US.
The benefit of adding rituximab to a chemotherapy regimen consisting of fludarabine + cyclophosphamide (FC) was assessed in two phase III trials, both showing improvements in progression-free survival and tumour response for patients treated with rituximab in comparison to patients treated with chemotherapy only. Based on these trials, rituximab + FC has increasingly become standard therapy for younger and fitter patients in the first-line setting. For previously treated patients, it remains unclear if patients will benefit when retreated with this combination therapy.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Keywords:||Rituximab, Rituxan, MabThera, monoclonal antibody, CLL, NHL, Oncology|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WH Hemic and lymphatic systems
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
|Series Name:||DSD: Horizon Scanning in Oncology 04 / Update 2011|
|Deposited on:||07 Dec 2011 16:17|
|Last Modified:||07 Dec 2011 16:52|
Repository Staff Only: item control page